Our Pricing

Is Wegovy Good For Weight Loss? Clinical Evidence

Published on: June 03, 2026

Is Wegovy good for weight loss UK patients ask frequently, and the clinical evidence is compelling. Wegovy (semaglutide 2.4mg) demonstrated an average 15% body weight reduction in the landmark STEP trials, making it one of the most effective prescription weight loss treatments licensed by the MHRA [1]. At Cured Pharmacy, Wegovy is available from £79.00 following a free online consultation with our UK-registered prescribers.

How Wegovy Works for Weight Loss

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural hormone your body produces after eating [1]. This medication works through three primary mechanisms: it slows gastric emptying so you feel fuller for longer, reduces appetite signals in the brain, and improves blood sugar regulation. Unlike older weight loss medications that target only one pathway, semaglutide's multi-faceted approach addresses the complex biological drivers of obesity.

The 2.4mg dose used in Wegovy is specifically optimised for weight management, higher than the doses used for type 2 diabetes treatment. Clinical pharmacology studies show peak semaglutide concentrations occur 1-3 days after injection, with steady-state levels achieved after 4-5 weeks of consistent weekly dosing [2]. This explains why prescribers gradually increase your dose over 16-20 weeks rather than starting at the full therapeutic level.

Wegovy Clinical Trial Results: The STEP Programme Evidence

The STEP (Semaglutide Treatment Effect in People with obesity) trials represent the gold standard evidence for is Wegovy good for weight loss questions. STEP 1, the largest trial involving 1,961 adults with obesity, showed participants lost an average 14.9% of their initial body weight over 68 weeks compared to 2.4% with placebo [1]. More impressively, 86.4% of Wegovy users achieved at least 5% weight loss, whilst 69.1% lost 10% or more.

STEP 2 specifically examined semaglutide in patients with type 2 diabetes and overweight, demonstrating average weight loss of 9.6% versus 3.4% with placebo over 68 weeks [3]. This trial confirmed Wegovy's effectiveness even in metabolically complex patients. STEP 3 combined semaglutide with intensive behavioural therapy, achieving remarkable 16% average weight reduction [4]. Across all STEP trials, weight loss was accompanied by improvements in waist circumference, blood pressure, cholesterol levels, and inflammatory markers.

Long-Term Weight Maintenance Data

The STEP 4 trial addressed a critical question: what happens when you stop Wegovy? Participants who discontinued semaglutide after 20 weeks regained approximately two-thirds of their lost weight over the following year, whilst those continuing treatment maintained their weight loss [5]. This evidence demonstrates Wegovy works as a long-term weight management medication rather than a short-term fix, similar to how blood pressure medications require ongoing use to maintain therapeutic benefits.

Who Is Wegovy Suitable For in the UK?

MHRA licensing and NICE guidance specify Wegovy is indicated for adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnoea [6]. Your UK prescriber will calculate your BMI during consultation and assess whether you meet clinical criteria. Wegovy is not licensed for cosmetic weight loss in individuals at healthy weight ranges.

Certain medical conditions require careful evaluation before starting Wegovy. The medication is contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [2]. Your prescriber will also review your history of pancreatitis, severe gastrointestinal disease, diabetic retinopathy, and current medications. Pregnant or breastfeeding women should not use Wegovy, and effective contraception is recommended during treatment due to limited safety data.

Wegovy Dosing Schedule and What to Expect

Wegovy treatment follows a structured dose escalation protocol designed to minimise gastrointestinal side effects whilst optimising weight loss. You begin with 0.25mg weekly for four weeks, then increase monthly through 0.5mg, 1mg, and 1.7mg doses before reaching the maintenance dose of 2.4mg [2]. This gradual titration allows your body to adapt to semaglutide's effects on gastric emptying and appetite.

Most patients begin noticing appetite reduction within the first 2-4 weeks, even at lower starter doses. Measurable weight loss typically becomes evident by week 8-12, with progressive reduction continuing through the first year of treatment. Clinical trial data shows the majority of weight loss occurs in the first 60 weeks, after which weight tends to stabilise at a new lower baseline [1]. Your UK prescriber will monitor your progress at regular intervals and may adjust your treatment plan if you experience tolerability issues or inadequate response.

Injection Technique and Storage

Wegovy pens are pre-filled single-use injectors administered subcutaneously once weekly, on the same day each week. You can inject into your abdomen, thigh, or upper arm, rotating injection sites to prevent lipodystrophy. The pens must be stored in a refrigerator between 2-8°C before first use, though they can remain at room temperature up to 30°C for up to 28 days if needed for travel [2]. Each pen contains four doses at the appropriate strength for your current phase of treatment.

Common Side Effects and How to Manage Them

Gastrointestinal effects are the most frequently reported side effects with Wegovy, occurring in approximately 44% of trial participants [1]. Nausea, typically mild to moderate, is most common during dose escalation phases and usually diminishes within 4-8 weeks as your body adapts. Other digestive effects include diarrhoea, constipation, vomiting, and abdominal discomfort. These symptoms are generally transient and can be managed through dietary modifications such as eating smaller portions, avoiding high-fat meals, and staying well-hydrated.

Serious adverse events are rare but require awareness. Acute pancreatitis occurred in 0.2% of semaglutide users versus 0.1% with placebo in pooled trial data [3]. Warning signs include severe persistent abdominal pain radiating to the back, often accompanied by vomiting. Gallbladder problems, including cholelithiasis, occurred more frequently with rapid weight loss. Hypoglycaemia risk is low in non-diabetic patients but may occur if you're taking other glucose-lowering medications. Your prescriber will provide detailed safety information and advise when to seek medical attention.

Is Wegovy Good for Weight Loss Compared to Alternatives?

When evaluating is Wegovy good for weight loss against other UK-licensed options, head-to-head trial data provides valuable context. Semaglutide 2.4mg demonstrated superior weight loss compared to liraglutide 3mg (Saxenda), with average reductions of 15.8% versus 6.4% respectively in the STEP 8 trial [7]. Wegovy users were significantly more likely to achieve 10%, 15%, and 20% weight loss thresholds. However, newer dual GIP/GLP-1 receptor agonists have shown even greater efficacy in recent trials.

Orlistat, the only non-prescription weight loss medication available in UK pharmacies, works through an entirely different mechanism by blocking fat absorption in the intestines. Whilst orlistat is more accessible and lower cost, clinical trials show average weight loss of just 3-5% compared to Wegovy's 15% [8]. The choice between treatments depends on your clinical profile, tolerance for injections versus oral medication, budget considerations, and weight loss goals. Your UK prescriber at Cured Pharmacy will discuss which option aligns best with your individual circumstances, all subject to clinical assessment and approval.

Cost Considerations and Value

Wegovy represents a significant investment in your health, with treatment costs varying across UK pharmacy providers. At Cured Pharmacy, transparent upfront pricing from £79.00 per month ensures you understand costs before completing your clinical consultation. This competitive pricing includes your medication, prescriber assessment, and discreet delivery. Many patients find the clinical benefits—substantial weight loss, improved metabolic markers, and reduced obesity-related health risks—justify the ongoing cost when compared to potential long-term healthcare expenses associated with untreated obesity.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. Retrieved from https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
3. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
4. Wadden, T. A., Bailey, T. S., Billings, L. K., et al. (2021). Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA, 325(14), 1403–1413. https://doi.org/10.1001/jama.2021.1831 [accessed 13 August 2026]
5. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
6. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity: Technology appraisal guidance [TA875]. Retrieved from https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
7. Rubino, D. M., Greenway, F. L., Khalid, U., et al. (2022). Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA, 327(2), 138–150. https://doi.org/10.1001/jama.2021.23619 [accessed 13 August 2026]
8. Yanovski, S. Z., & Yanovski, J. A. (2014). Long-term Drug Treatment for Obesity: A Systematic and Clinical Review. JAMA, 311(1), 74–86. https://doi.org/10.1001/jama.2013.281361 [accessed 13 August 2026]
9. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
10. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
11. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.